Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease

• Published in: Movement disorders Vol. 21; no. 1; pp. 115 - 116
• Main Authors: Sullivan, Kelly L., Staffetti, Joseph F., Hauser, Robert A., Dunne, Peter B., Zesiewicz, Theresa A.
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.01.2006; Wiley
• Subjects: Aged; Biological and medical sciences; constipation; Constipation - drug therapy; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Double-Blind Method; Female; Gastrointestinal Agents - administration & dosage; Gastrointestinal Motility - drug effects; Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy; Humans; Indoles - administration & dosage; Male; Medical sciences; Middle Aged; Nervous system (semeiology, syndromes); Neurology; Parkinson Disease - drug therapy; Parkinson's disease; Patient Satisfaction; Serotonin 5-HT4 Receptor Agonists; Serotonin Receptor Agonists - administration & dosage; tegaserod; Zelnorm; Nervous system diseases; Parkinson's disease; Parkinson disease; Cerebral disorder; Zelnorm; Treatment; Central nervous system disease; Digestive diseases; Intestinal disease; Degenerative disease; Constipation; Tegaserod; Extrapyramidal syndrome
• ISSN: 0885-3185; 1531-8257
• DOI: 10.1002/mds.20666

We performed a double‐blind randomized placebo‐controlled pilot study to determine the efficacy of tegaserod (Zelnorm) in treating constipation in 15 patients with Parkinson's disease (PD). There was a trend for improvement in the Subject's Global Assessment (SGA) of satisfaction with bowel habits (NS) and the total SGA (including abdominal discomfort, bothersome constipation, and satisfaction; NS). © 2005 Movement Disorder Society